116 results about "Blood group antigens" patented technology

The present invention provides methods for in vitro production of clinically useful quantities of differentiated human blood cells. In various embodiments of the present invention, immortal pluripotent cells are used to produce differentiated blood cell populations using a cell production device. In a specific embodiment, the device is a sequential series of bioreactors utilizing growth media containing specific combinations of maintenance-, proliferation- or differentiation-promoting factors that maintain, expand and promote the maturation and differentiation of the desired cell types. The immortal pluripotent cells can optionally be genetically modified so as to remove histcompatibility or blood group antigens.

The present invention provides carbohydrate encapsulated nanoparticles. In particular, the present invention provides metallic nanoparticles (e.g. gold nanoparticles) that are encapsulated in biologically important carbohydrate molecules, such as sugars, sugar derivatives, P-blood group antigens and analogues thereof. The present invention also provides methods of employing these carbohydrate encapsulated nanoparticles in diagnostic and therapeutic applications.

Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.

RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC / c, RhE / e, S / s, K / k, Kpa / b, Fya / b, FYO, Jka / b, Dia / b, and HPA-1a / b.

The invention provides a method for preserving the activity of a human cell membrane blood group antigen, which comprises the steps of: preparing an erythrocyte membrane blood group antigen extract, and then coating the prepared erythrocyte membrane blood group antigen on a solid microsphere so as to replace a fresh erythrocyte to be used for detecting a blood group antibody in a sample.

The invention discloses a reverse typing colloidal gold kit for ABO blood groups and a preparation method thereof. The reverse typing colloidal gold kit for the ABO blood groups comprises a reacting plate, erythrocyte membrane antigen gold particles and a basic solution, wherein 3N reaction holes are formed in the reacting plate and are respectively used for placing A erythrocyte membrane antigen gold particles and a basic solution, B erythrocyte membrane antigen gold particles and a basic solution, and O erythrocyte membrane antigen gold particles and a basic solution; the reaction holes are of circular structures, the bottoms of the holes are smooth and U-shaped; and sealing covers are arranged on the reaction holes. The kit also can be a dry kit; and the erythrocyte membrane antigen gold particles and the basic solution are dried on the reaction holes. According to the reverse typing colloidal gold kit for the ABO blood groups and the preparation method, erythrocyte membrane blood group antigen extracts are prepared and then marked with the colloid gold, and thereby the problem that the fresh erythrocyte just can be stored in a short period can be solved. The kit has the shelf life not less than 12 months at 2 to 20 DEG C, and has the advantages of being high in sensitivity, convenient to use, and relatively low in cost, and identifying the results easily.

The invention relates to a method for the immunodetection of human blood group antibodies, particularly relating to a method and a used detection strip for rapidly detecting human blood group antibodies. The method comprises the following steps: a blood group antigen is precoated on a solid-phase carrier; the blood group antigen with a signal mark is fixed on a fiber mat adhered on one end of the carrier; and a sample is added dropwise, if the sample to be detected contains an antibody which can be combined with the blood group antigen, a macroscopic immune complex can be observed on the solid-phase carrier, and otherwise, the macroscopic immune complex is not formed, thus the blood group antibody in the sample is detected.

The invention relates to the technical field of biology, and particularly discloses a canine single-chain antibody, and a construction method and application thereof. By designing the canine antibody variable region degenerate primers, the canine heavy chain variable region VH and light chain variable region VL genes are successfully amplified. On such basis, a bacteriophage display technique is utilized to successfully construct the canine single-chain antibody scFv library. The scFv single-chain antibody library has diversity and enough storage capacity. A Dot-ELISA method is utilized to screen 3 single chain antibodies capable of being combined with the canine DEA 1.1 blood group antigen from the scFv single-chain antibody library by using the canine DEA 1.1 blood group antigen, wherein Clone 16 has stronger combination characteristic. A pET-32a-Clone16 recombinant protein is constructed according to the Clone 16 gene to perform prokaryotic expression, and the purified antibody has combination activity. The canine single-chain antibody lays solid foundation for preparing canine DEA 1.1 blood grouping reagents.

The invention relates to a testing method for red corpuscle blood group antigen. It takes the processes of over pre-dilution, reacting, and testing, respectively testing the reacting system formed by tested red corpuscle and blood group antibody that is already known and the red corpuscle parameter of the comparing system constructed by the tested red corpuscle suspension without blood group antibody, gaining the alteration of the two system red corpuscle parameters, taking comparison analysis to the restricted range to judge whether the agglutination reaction is occurred and indirectly testing whether the tested red corpuscle has the blood type antibody corresponding to that has already been known.

A novel blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to Helicobacter pylori fucosylated blood group antibodies. Said adhesin has a molecular weight of about 73.5 kDa and the N-terminal sequence for the adhesin and the corresponding DNA show homologies between different strains of H. pylori. Said adhesin and / or DNA is useful for diagnose and therapy and / or profylax directed against H. pylori induced infections, e.g. gastritis and acid peptic disease.

The invention relates to a preparation method of an ABO / RhD blood group antigen detection reagent card. Eight microcolumn gel tubes are arranged on the detection reagent card, wherein two gel tubes contain gel and anti-A monoclonal antibodies with an immunoglobulin m (IgM) property, two gel tubes contain gel and anti-B monoclonal antibodies with the IgM property, two gel tubes contain gel and anti-D monoclonal antibodies of RhD blood type with the IgM property, and two gel tubes contain a gel suspending medium buffer solution and gel.

Lactobacillus screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 lactobacillus strains, the above-mentioned screening methods and tests to judge their compatibility for the use of yogurt production were carried out, to at long last specifically discover bacillus strains compatible with blood groups A, B, and O.

The invention discloses a blood group antigen chip and application thereof in detection of unexpected erythrocyte antibodies. The detection comprises: (1) coating a carrier with a blood group erythrocyte membrane antigen; (2) contacting a tested sample with the antigen of the carrier; (3) adding a second antibody labeled with a marker; and (4) performing signal detection on the marker. The blood group antigen chip and a detection method of unexpected erythrocyte antibodies are high in sensitivity, good in accuracy, independent of erythrocytes, and capable of detecting binding antibodies of a plurality of rare blood group antigens.

The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.

The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been bioligically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The present invention relates to methods of detecting specific cell surface antigens present in a sample of cells being tested and in particular blood group antigens, which methods do not employ the addition of extrinsic labels to detect said cell surface antigens. Typically detection is carried out using an intrinsic fluorescence capability of the cells being tested.

Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.

A novel Helicobacter pylori blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antigens. The protein sequence of said adhesin is disclosed in this application. Simultaneously the DNA sequences for two genes, babA and babB, producing highly similar proteins, are disclosed. Said adhesin and / or DNA is useful for diagnose and therapy and / or prophylaxis directed against H. pylori induced infections, e.g. gastritis and acid peptic disease, i.e. active vaccination. A new immunoglobulin composition, which exhibits specific activity to a Lewisantigen binding Helicobacter pylori adhesin, or preferably, monoclonal and / or polyclonal antibodies to said adhesin offer a new and more efficient method of treatment and / or prevention of gastrointestinal diseases, caused by Helicobacter pylori or other Helicobacter species, i.e. passive vaccination.

The invention relates to a casset based on solid-phase type quick blood grouping and a grouping method. The casset comprises a casset body, a sample groove, an antibody groove and a gold mark groove,wherein the sample groove is arranged in the middle part of the casset body; the antibody groove is arranged at one side of the sample groove; the gold mark groove is arranged at the other side of thesample groove; a monoclonal antibody is arranged in the antibody groove; a gold mark erythrocyte membrane antigen is arranged in the gold mark groove; an upper water absorbing paper is arranged between the sample groove and the antibody groove; a blood filtering membrane is arranged between the sample groove and the gold mark groove; a lower water absorbing paper is arranged under the blood filtering membrane. The casset has the advantages that the anti-A, anti-B and anti-D specific monoclonal antibodies are used as positive typing reagents of A, B and O blood groups, the A, B and O blood group antigens (gold mark antigens) marked with the specific erythrocyte membranes are used as reverse typing immune colloidal gold reagents, and the positive and reverse typing reagents are respectivelyarranged on the casset body; the operation is simple and quick, the carrying is convenient, the accuracy is high, the casset is suitable for the condition that the positive and reverse typing reagents of the blood group typing reagent are simultaneously placed into a blasting ball at mobile blood collection sites and during emergency blood transfusion.

Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum / plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.

A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia. The composition contains a therapeutically effective amount of a binding-inhibiting compound selected from Compounds 1 through 15, and at least one diluent, carrier or excipient. The Compounds competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions can be administered to a human prior to or after infection by a Norovirus, to prevent or ameliorate an infection.

The invention discloses a Miltenberger blood group antibody detection immunofluorescent chromatography test strip and a detection method thereof. The Miltenberger blood group antibody detection immunofluorescent chromatography test strip comprises a sample pad, a reaction film and an absorption pad which are in an ordinal overlap joint relationship. Two ends of the sample pad are provided with a first sample injection point and a second sample injection point. An inner quality control band and at least one antibody detection band are fixed to the reaction film. The detection method comprises the following steps of mixing a biotin-labelled polypeptide blood group antigen and a serum sample, adding the mixture into the sample pad, adding a fluorescent label second antibody into the sample pad, and carrying out detection by a fluorescence detector. The Miltenberger blood group antibody detection immunofluorescent chromatography test strip solves the problem that a simple and practical clinical conventional Miltenberger blood group antibody detection technology and a reagent are deficient, is used for assistant clinical diagnosis of Miltenberger blood group antibody-caused hemolytic disease of the newborn, and adverse effects of blood transfusion, and guarantees clinical safety, effectiveness and scientific blood transfusion.

The invention relates to a synthesis method of saccharides, in particular to synthesis of ABH blood group antigen. The synthesis method comprises the following steps: through a one-pot and multi-enzyme system, coupling fucose to disaccharide shown as a formula (I) by using an alpha1-2 glucosidic bond to synthesize trisaccharide shown as a formula (II); through the one-pot and multi-enzyme system,coupling galactose to the trisaccharide shown as the formula (II) by using an alpha1-3 glycosidic bond to synthesize tetrasaccharide shown as a formula (III); through the one-pot and multi-enzyme system, coupling N-acetylgalactosamine to the trisaccharide shown as the formula (II) by using the alpha1-3 glycosidic bond to synthesize tetrasaccharide shown as a formula (IV). Through utilization of enzymatic modular assembly and full utilization of the high efficiency of various enzymes and the specificity of a substrate, the synthesis of the ABH blood group antigen is completed.

The invention discloses a human killer cell immunoglobulin-like receptor (KIR) genotyping inspection primer group, comprising 16 pairs of primers shown in SEQ ID No.1-32. On the basis of the reactiontheory of polymerase chain reaction (fluorescence PCR) in the invention, the first basic group at the end of primer 3' is complementary to the specific basic group of an allele, specific primer pairsonly amplify alleles matched with the same; the primer design is based on human gene sequence issued by Blood Group Antigen Gene Mutation Database (dbRBC) in DNA sequence database (Genbank) that is established by National Center for Biotechnology Information (NCBI), proper specific mutation point is selected to design primers; a PCR doped dye method uses fluorescent dye to show DNA amplification effect through doping the amplified product of DNA. Melting curve analysis is carried out after amplification, and as a result, whether the target product is amplified specifically can be determined through the melting curve analysis, thereby identifying alleles.

The invention is a method of preparing the red corpuscle of low-expression blood group antigen adopting at least one immunodominant glucoamylase, such as N-acetylgalactosaminase or Alpha-galactosidase. The antigen expressed by the red corpuscle which is prepared by the method only reaches the threshold value of the antigen level that can be detected at clinic substantively. The red corpuscle prepared by this process can be applied to the quality control of the blood group reagent and the adjustment of the testing system, therefore can judge the blood group accurately and standardly.